Organon & Co. (OGN)
NYSE: OGN · Real-Time Price · USD
9.45
-3.48 (-26.91%)
At close: May 1, 2025, 4:00 PM
9.41
-0.04 (-0.42%)
After-hours: May 1, 2025, 6:38 PM EDT
Organon & Co. Revenue
Organon & Co. had revenue of $1.51B in the quarter ending March 31, 2025, a decrease of -6.72%. This brings the company's revenue in the last twelve months to $6.29B, down -0.84% year-over-year. In the year 2024, Organon & Co. had annual revenue of $6.40B with 2.24% growth.
Revenue (ttm)
$6.29B
Revenue Growth
-0.84%
P/S Ratio
0.53
Revenue / Employee
$629,400
Employees
10,000
Market Cap
2.46B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.19B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
OGN News
- 6 hours ago - Organon & Co. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - OGN - Business Wire
- 6 hours ago - OGN Investors Have Opportunity to Join Organon & Co. Fraud Investigation with the Schall Law Firm - Business Wire
- 10 hours ago - Organon & Co. (OGN) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 14 hours ago - Organon Reports Results for the First Quarter Ended March 31, 2025 - Business Wire
- 16 days ago - Organon Appoints Ramona A. Sequeira to the Company's Board of Directors - Business Wire
- 16 days ago - Organon To Report First Quarter 2025 Results and Host Conference Call on May 1, 2025 - Business Wire
- 4 weeks ago - Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S. - Business Wire
- 4 weeks ago - European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11 - Business Wire